🔗 Share this article

As America continues making sweeping revisions to its vaccination recommendations, an unexpected name has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent physician and public health researcher who rose to prominence by casting doubt on coronavirus vaccinations throughout the global health crisis and has concentrated on possible deaths following COVID-19 vaccination in her short time at the Food and Drug Administration.

Proposed Shifts to Childhood Immunization Schedule

Public health authorities had intended to announce radical changes to the pediatric immunization program in December, bringing the US with Denmark’s national calendar, according to reports – a substantial departure that would put the US at odds with many the international standard with insufficient data for benefit. The planned update has been postponed until the next year.

Rather than Vinay Prasad, Tracy Beth Høeg is set to present at the gathering. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to lead the office this calendar year.

A Shift at the FDA

Høeg's temporary position may indicate a strengthened alliance between the drug and biologics centers as Dr. Høeg and Dr. Prasad consolidate power at the FDA – and it points to a increased emphasis upon rolling back previously authorized immunizations at the FDA.

Høeg has repeatedly called for halting certain pediatric immunization guidelines in the US in order to be more similar to Denmark's approach, a society with nationalized medicine and a population about the population of the state of Wisconsin.

So far comments, she has continued to focus on vaccination policy – traditionally the responsibility of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Concerns Over Background

Høeg has no obvious track record in pharmaceutical research, oversight or management, which has been standard for past directors of the biologics center. She has been employed at the FDA as a key advisor to the agency head and the vaccine center since earlier this year.

“It seems she lacks to have any of the qualifications” for overseeing the drug-regulation department, said a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She has no expertise in leading a sizeable institution. She lacks background in pharmaceutical oversight.”

Previous commissioners of the center would “be deeply familiar with regulatory frameworks and the research of drug development”, noted a former acting FDA commissioner. “Clearly, she doesn’t have the type of experience that former directors who ran CBER have had.”

The drug center has an immense range of responsibilities at the FDA, she emphasized.

“Everybody just focuses on the novel medication approvals, but the generic program approves numerous generic medications. There is also a biosimilars program, non-prescription drug unit and more, and every single one have to be managed,” she explained. “The responsibility you overlook, that is the part that I always told people is going to cause problems.”

Furthermore, a substantial leadership component to the role, which oversees in excess of 5,000 staff members. “It’s a enormous leadership role, if you perform it correctly,” she concluded.

Official Statement and Controversial Policies

Regarding questions about Høeg’s fitness for the role and whether this appointment represents increased cooperation among regulatory chiefs on immunizations, a spokesperson said that the “questions rely on incorrect presumptions”.

“Her experience matches the duties of her position,” the representative said, citing the time Høeg spent guiding the FDA commissioner on “medication safety and oversight research, including computerized risk analysis and shot safety tracking”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's recently launched expedited review system, a controversial expedited therapy clearance system that allegedly concerned her preceding directors. “By what process are these drugs being selected for this voucher program? Who takes the choices?” Howard asked. “There’s a lot of lack of transparency happening at the agency right now.”

Overall, he stated, “the agency looks to be trending towards more relaxed oversight of all drugs, aside from immunizations.”

Public Past Work on Vaccines

Concerning vaccines, Dr. Høeg has a more documented, if problematic, history, Howard said. She published a analysis using non-validated volunteer-provided data to determine the rate of heart inflammation following Covid immunization. She counseled the Florida chief medical officer Joseph Ladapo, who reportedly have altered data to suggest COVID-19 vaccines are more dangerous than they are.

Among her “desired changes” for the new government included revising regulations for novel immunizations and ending “non-essential” immunizations, she said post-election on a online show. At the FDA, Høeg has reportedly suggested excluding adolescent males from getting Covid vaccines.

“She’s an all-around true believer who starts off with her preconceived notions and works backwards to retrofit the data in a highly misleading, dishonest fashion,” Howard stated.

Gaining Influence and a “Campaign of Retribution”

Høeg became part of fellow dissenters, {like|